OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%

MT Newswires Live

6 hours ago

OncoSil Medical (ASX:OSL) received positive preliminary results from an investigator-initiated study, indicating that it is "safe and feasible" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.

OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.

The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.

The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.

Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.

OncoSil Medical shares rose 14% in morning trade Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568449281"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568449281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568449281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568449281","market":"hk","top_or_hot":-1,"title":"OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%","media":"MT Newswires Live","content":"<html><body><p> OncoSil Medical (ASX:OSL) received positive preliminary results from an investigator-initiated study, indicating that it is \"safe and feasible\" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.</p><p>OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.</p><p>The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.</p><p>The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.</p><p>Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.</p><p>OncoSil Medical shares rose 14% in morning trade Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSil Medical Receives Positive Preliminary Results From Investigator-Initiated Pancreatic Cancer Study; Shares Up 14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-18 09:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OncoSil Medical (ASX:OSL) received positive preliminary results from an investigator-initiated study, indicating that it is \"safe and feasible\" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.</p><p>OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.</p><p>The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.</p><p>The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.</p><p>Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.</p><p>OncoSil Medical shares rose 14% in morning trade Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7048","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568449281","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568449281","pubTimestamp":1758158297,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OncoSil Medical  received positive preliminary results from an investigator-initiated study, indicating that it is \"safe and feasible\" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.OncoSil Medical shares rose 14% in morning trade Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7048":"生命科学工具和服务","OSL.AU":"ONCOSIL MEDICAL LTD","BK7508":"医药生物股"},"translate_title":"OncoSil Medical从研究者发起的胰腺癌研究中获得积极的初步结果；股价上涨14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSL.AU":1},"content_text":"OncoSil Medical (ASX:OSL) received positive preliminary results from an investigator-initiated study, indicating that it is \"safe and feasible\" to deliver OncoSil by computerized tomography-guided percutaneous administration, according to a Thursday filing with the Australian bourse.OncoSil is a medical device that delivers a targeted dose of radiation directly into cancerous tissue in locally advanced pancreatic cancer.The procedure had a 90% technical success rate, with 10% of patients experiencing third-grade serious adverse device events, the filing said.The company anticipates securing additional regulatory approvals in the second half of fiscal 2026.Pancosil is a first-in-the-world study administering OncoSil through direct injection through the skin, according to the filing.OncoSil Medical shares rose 14% in morning trade Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}